Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two-dimensional pixel-level addressable mid-infrared metasurface spatial light modulator.

Nature communications·2026
Same author

A rare convergence: Pleural amyloidosis in H syndrome - A diagnostic surprise in a young Indian male.

Lung India : official organ of Indian Chest Society·2026
Same author

FOXO transcription factors in Alzheimer's Disease: balancing neuroprotection and neuronal degeneration.

Molecular biology reports·2026
Same author

Advances and emerging perspectives in arsenic bioremediation: a review study on mechanisms and innovations.

Environmental geochemistry and health·2026
Same author

Acute Megakaryoblastic Leukemia with Concurrent Hemophagocytosis and Cannibalism in an Infant: A Rare Case with Novel t(7;16)(p15;p13.1) Translocation.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Translational advances of exosomes in neurodegeneration towards precision healthcare: From biomarkers to therapeutic frontiers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Apr 14, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

547

NGS-Based Mutation Profiling and PD-L1 Expression in NSCLC Patients: A Single-Centre Prospective Analysis.

Anab Sayyada1, Dheeraj Gautam1, Rashi Sharma1

  • 1Department of Pathology and Lab Medicine, Medanta-The Medicity, HARYANA, INDIA.

Turk Patoloji Dergisi
|April 13, 2026
PubMed
Summary

Next-generation sequencing (NGS) and PD-L1 testing in non-small cell lung cancer (NSCLC) reveal distinct molecular profiles. Lower PD-L1 expression in EGFR-mutant NSCLC and higher expression in KRAS-mutant NSCLC guide personalized treatment strategies.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Related Experiment Videos

Last Updated: Apr 14, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

547
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is characterized by molecular heterogeneity, impacting treatment decisions.
  • Actionable mutations and programmed death-ligand 1 (PD-L1) expression are critical biomarkers for NSCLC therapy.
  • Personalized medicine approaches require comprehensive molecular profiling.

Purpose of the Study:

  • To evaluate the molecular profile of NSCLC using next-generation sequencing (NGS).
  • To analyze the association between PD-L1 expression and key genetic alterations in NSCLC.
  • To inform personalized therapeutic strategies by integrating molecular and immunophenotypic data.

Main Methods:

  • Retrospective analysis of 87 histopathologically confirmed NSCLC cases.
  • Molecular profiling using the Oncomine™ Lung Focus Assay for actionable mutations.
  • PD-L1 expression assessment via immunohistochemistry (IHC) using Tumour Proportion Score (TPS).

Main Results:

  • EGFR (36.2%), KRAS (16.2%), and AR amplification (14.3%) were the most frequent alterations.
  • Actionable mutations were identified in 59.8% of patients, including EGFR, ALK, ERBB2, KRAS, MET, BRAF, and ROS1 alterations.
  • PD-L1 expression (45.7%) was lower in EGFR-mutant tumors and higher in KRAS-mutant tumors, suggesting differential immunogenicity and potential predictive value for immunotherapy.

Conclusions:

  • Integrating NGS-based molecular testing with PD-L1 evaluation is crucial for personalized NSCLC management.
  • Distinct PD-L1 expression patterns across molecular subtypes (e.g., EGFR vs. KRAS mutations) necessitate tailored therapeutic strategies.
  • Informed sequencing of targeted therapies and immunotherapies can be achieved through comprehensive molecular profiling.